Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Gastroenterol Clin North Am. 2019 Apr 1;48(2):319–330. doi: 10.1016/j.gtc.2019.02.005

FIGURE 1: Schematic representation of the most commonly used recombinant AAV serotype vectors and their tissue-tropism.

FIGURE 1:

Various murine tissues and organs that have been reported to be transduced efficiently with various AAV serotype vectors are indicated. AAV3 serotype vectors in particular, have been shown to transduce human hepatocytes well. Data from Glushakova LG, Lisankie MJ, Eruslanov EB, et al.. AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol Genet Metab 2009;98:289-99, Cheng B, Ling C, Dai Y, et al.. Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther 2012; 19:375-84, Ling C, Wang Y, Zhang Y, Ejjigani A, Yin Z, Lu Y, Wang L, Wang M, Li J, Hu Z, Aslanidi GV et al.: Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum Gene Ther (2014) 25(12):1023-1034, Ling C, Lu Y, Kalsi JK, Jayandharan GR, Li B, Ma W, Cheng B, Gee SW, McGoogan KE, Govindasamy L, Zhong L et al.: Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther (2010) 21 (12):1741- 1747, Li S, Ling C, Zhong L, Li M, Su Q, He R, Tang Q, Greiner DL, Shultz LD, Brehm MA, Flotte TR et al.: Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3b vectors. Mol Ther (2015) 23(12):1867-1876, Wang L, Bell P, Somanathan S, Wang Q, He Z, Yu H, McMenamin D, Goode T, Calcedo R, Wilson JM: Comparative study of liver gene transfer with AAV vectors based on natural and engineered aav capsids. Mol Ther (2015) 23(12):1877-1887, and Vercauteren K, Hoffman BE, Zolotukhin I, et al.. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther 2016;24:1042-49 with permission.